Clinical trials: Psoriasis Patients
Psoriasis, Plaque Psoriasis
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.
- Trial name
- NCT04603027
- Testing
- EDP1815
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 249 people
- Sponsor
- Evelo Biosciences, Inc.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Plaque Psoriasis
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis (INDUS-3)
- Trial name
- INDUS-3 (NCT04855721)
- Testing
- AUR101
- Where
- 25 sites in United States
- Volunteers
- 141 people
- Sponsor
- Aurigene Discovery Technologies Limited
Psoriasis
Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting
Study is not recruiting and using secondary data sources only
- Trial name
- NCT04799990
- Testing
- Risankizumab, Comparator 1, Comparator 2
- Sponsor
- AbbVie
Chronic Plaque Psoriasis
Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult…
- Trial name
- DERMIS-1 (NCT04211363)
- Testing
- Roflumilast 0.3% cream, Vehicle Cream
- Where
- 40 sites in United States, Canada
- Volunteers
- 439 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Chronic Plaque Psoriasis
Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
This study will assess the safety and efficacy of ARQ-151 cream vs placebo applied once a day for 56 days by subjects with chronic plaque psoriasis
- Trial name
- DERMIS-2 (NCT04211389)
- Testing
- ARQ-151 0.3% cream, ARQ-151 vehicle cream
- Where
- 39 sites in United States, Canada
- Volunteers
- 442 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Palmoplantar Pustulosis (PPP)
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
Palmoplantar pustulosis is a chronic inflammatory skin disease that causes repeated on and off symptoms like erythema (reddening, irritation), vesicle (swelling, cyst), pustules, scale, and crusts in palms and soles.
- Trial name
- NCT04451720
- Testing
- Risankizumab
- Where
- 39 sites in Japan
- Volunteers
- 119 people
- Sponsor
- AbbVie
Psoriasis
A Study of LY3361237 in Participants With Psoriasis
The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis.
- Trial name
- NCT04975295
- Testing
- LY3361237
- Where
- 7 sites in Bulgaria, Hungary and 2 more
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company
Plaque Psoriasis
An Open-Label Study to Assess Safety
An Open-Label study to assess safety
- Trial name
- NCT03645499
- Testing
- Topical TA-102 A, Topical TA-102 B, Topical TA-102 C
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
To assess long-term safety, tolerability, and efficacy of BI 730357 in patients with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03835481
- Testing
- BI 730357
- Where
- 30 sites in United States, Canada and 1 more
- Volunteers
- 165 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
The study was conducted to describe the demographics, disease characteristics, disease severity, comorbidities and patient reported outcomes at baseline and follow-up periods among adult patients diagnosed with PsO in CorEvitas'…
- Trial name
- NCT05513014
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 1,518 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05604898
- Testing
- Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
- Where
- 3 sites in China
- Volunteers
- 139 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Plaque Psoriasis
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
The aims is to evaluate the efficacy and comparative isolation of the association Mometasone furoate + Salicylic Acid and the substance isolated Mometasone furoate produced by the Laboratory Glenmark Pharmaceuticals Ltd.
- Trial name
- Psoriasis (NCT01228656)
- Testing
- mometasone furoate + salicylic acid, Mometasone furoate
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Psoriasis
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03219437
- Testing
- risankizumab, methotrexate
- Where
- 11 sites in Brazil
- Volunteers
- 104 people
- Sponsor
- AbbVie
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis
The purpose of this study is to investigate BMS-986165 given to Japanese participants with moderate-to-severe psoriasis.
- Trial name
- NCT03924427
- Testing
- BMS-986165
- Where
- 27 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
This study will assess the safety and efficacy of ARQ-154 foam vs placebo applied once a day for 56 days by subjects with scalp and body psoriasis
- Trial name
- NCT04128007
- Testing
- Roflumilast foam 0.3%, Vehicle foam
- Where
- 47 sites in United States, Australia and 2 more
- Volunteers
- 304 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
- Trial name
- BE ABLE 2 (NCT03010527)
- Testing
- Bimekizumab
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 217 people
- Sponsor
- UCB Biopharma SRL
Atopic Dermatitis, Psoriasis
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.
- Conditions
- Atopic Dermatitis, Psoriasis, Asthma
- Trial name
- NCT04927195
- Testing
- EDP1867
- Where
- 7 sites in United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Evelo Biosciences, Inc.
Plaque Psoriasis
Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.
The purpose of this investigation is to assess performance and safety of BIOpH+ Psoriasis Medical Bath in comparison to a comparative device.
- Trial name
- NCT05046899
- Testing
- BIOpH+ Psoriasis Medical Bath, Cetaphil Moisturizing Lotion
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Biocool AB
Plaque Psoriasis
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
The aim of this study is to investigate the utility of a technological based rating scale for assessing improvement in plaque psoriasis with Clobex spray treatment.
- Trial name
- NCT01893567
- Testing
- Clobex Spray
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Galderma R&D